Slides
Page 1
Not for promotional use
Page 2
Not for promotional use 2 This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation and investigations; business development transactions; trade and economic conditions; and changes in laws and regulations, including healthcare reform. For additional information about the factors that affect the company's business, please see the company's latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. These materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval or become commercially available for the uses being investigated. The company undertakes no duty to update forward-looking statements except as required by applicable law. Safe Harbor Provision and Other Information
Page 3
Broad portfolio of medicines across expanded indications Globally launched and widely available, with 13 sites under construction Increasing government and employer coverage, new alternative access models Innovative consumer mindset including LillyDirect platform PORTFOLIO SUPPL Y ACCESS Single marketed product Demand outpacing supply Coverage and payer barriers DIRECT PATIENT ENGAGEMENT Conventional pharma model Entering NEW ERA in treating people with obesity and related complications Portfolio Supply Access Direct patient engagement FROM TO 3Not for promotional use
Page 4
Expanding focus to help even more patients Not for promotional use 4 Launch & Late Phase Programs Additional Clinical Stage Programs BROAD PIPELINE POTENTIAL TO HELP 1B PEOPLE Obesity Diabetes Obstructive Sleep Apnea Pain Cardiovascular InflammationNeuroscience Others Discovery Programs INCRETINS | AMYLINS | NOVEL TARGETS Renal Hepatic Studying Incretins in New Diseases TIRZEPATIDE ORFORGLIPRON ELORALINTIDE BRENIPATIDE RETATRUTIDE 6 34